MA37895A1 - Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité - Google Patents
Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésitéInfo
- Publication number
- MA37895A1 MA37895A1 MA37895A MA37895A MA37895A1 MA 37895 A1 MA37895 A1 MA 37895A1 MA 37895 A MA37895 A MA 37895A MA 37895 A MA37895 A MA 37895A MA 37895 A1 MA37895 A1 MA 37895A1
- Authority
- MA
- Morocco
- Prior art keywords
- autism
- schizophrenia
- treatment
- metabotropic glutamate
- allosteric modulators
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des dérivés éthynyle de formule (i) dans laquelle r1 représente un hydrogène ou un halogène ; r2 représente un alkyle en c1 à c3 ou -(ch2)m-o-ch3 ; n représente 2 ou 3 ; m représente 1 ou 2 ; ou leurs sels d'addition d'acide de qualité pharmaceutique, leurs mélanges racémiques, ou leurs énantiomères et/ou isomères optiques et/ou stéréo-isomères correspondants. Il a été observé que les composés de formule générale (i) sont des modulateurs allostériques du récepteur métabotropique du glutamate de sous-type 5 (mglur5) possédant des propriétés améliorées pour le traitement de la schizophrénie, de maladies cognitives, du syndrome de l'x fragile ou de l'autisme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12180209 | 2012-08-13 | ||
| PCT/EP2013/066443 WO2014026880A1 (fr) | 2012-08-13 | 2013-08-06 | Aryléthynyl-pyrimidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37895A1 true MA37895A1 (fr) | 2016-12-30 |
| MA37895B1 MA37895B1 (fr) | 2017-08-31 |
Family
ID=46851291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37895A MA37895B1 (fr) | 2012-08-13 | 2013-08-06 | Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9199971B2 (fr) |
| EP (1) | EP2882742B1 (fr) |
| JP (1) | JP5974179B2 (fr) |
| KR (1) | KR101747005B1 (fr) |
| CN (1) | CN104540815B (fr) |
| AR (1) | AR092097A1 (fr) |
| AU (1) | AU2013304212B2 (fr) |
| BR (1) | BR112015002921A2 (fr) |
| CA (1) | CA2880257C (fr) |
| CL (1) | CL2015000290A1 (fr) |
| CO (1) | CO7180198A2 (fr) |
| CR (1) | CR20150028A (fr) |
| CY (1) | CY1118595T1 (fr) |
| DK (1) | DK2882742T3 (fr) |
| EA (1) | EA025165B1 (fr) |
| ES (1) | ES2601511T3 (fr) |
| HR (1) | HRP20161692T1 (fr) |
| HU (1) | HUE030237T2 (fr) |
| IL (1) | IL237015A (fr) |
| LT (1) | LT2882742T (fr) |
| MA (1) | MA37895B1 (fr) |
| MX (1) | MX358011B (fr) |
| MY (1) | MY170255A (fr) |
| NZ (1) | NZ704858A (fr) |
| PE (1) | PE20150685A1 (fr) |
| PH (1) | PH12015500261B1 (fr) |
| PL (1) | PL2882742T3 (fr) |
| PT (1) | PT2882742T (fr) |
| RS (1) | RS55397B1 (fr) |
| SG (1) | SG11201501055SA (fr) |
| SI (1) | SI2882742T1 (fr) |
| TW (1) | TWI501958B (fr) |
| UA (1) | UA113223C2 (fr) |
| WO (1) | WO2014026880A1 (fr) |
| ZA (1) | ZA201500582B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| NZ703537A (en) * | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
| CN107849006B (zh) * | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DE602005007350D1 (de) * | 2004-06-01 | 2008-07-17 | Hoffmann La Roche | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors |
| WO2006048771A1 (fr) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| AU2008317544A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mGluR5 |
| US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| NZ603868A (en) * | 2010-07-09 | 2014-08-29 | Recordati Ireland Ltd | Novel spiroheterocyclic compounds as mglu5 antagonists |
| US8642626B2 (en) * | 2010-07-29 | 2014-02-04 | Taisho Pharmaceutical Co., Ltd. | Ethinyl-pyrazole derivative |
| PE20141168A1 (es) * | 2011-04-26 | 2014-09-22 | Hoffmann La Roche | Derivados de pirazolidin-3-ona |
| US20130123254A1 (en) * | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| LT2875000T (lt) * | 2012-07-17 | 2016-11-10 | F.Hoffmann-La Roche Ag | Ariletinilo dariniai |
| PL2900659T3 (pl) * | 2012-09-27 | 2017-02-28 | F.Hoffmann-La Roche Ag | Pochodne aryloetynylowe |
-
2013
- 2013-06-08 UA UAA201501613A patent/UA113223C2/uk unknown
- 2013-08-06 NZ NZ704858A patent/NZ704858A/en not_active IP Right Cessation
- 2013-08-06 PT PT137478277T patent/PT2882742T/pt unknown
- 2013-08-06 PL PL13747827T patent/PL2882742T3/pl unknown
- 2013-08-06 HU HUE13747827A patent/HUE030237T2/en unknown
- 2013-08-06 SG SG11201501055SA patent/SG11201501055SA/en unknown
- 2013-08-06 MY MYPI2015000358A patent/MY170255A/en unknown
- 2013-08-06 MX MX2015001599A patent/MX358011B/es active IP Right Grant
- 2013-08-06 PE PE2015000196A patent/PE20150685A1/es active IP Right Grant
- 2013-08-06 HR HRP20161692TT patent/HRP20161692T1/hr unknown
- 2013-08-06 ES ES13747827.7T patent/ES2601511T3/es active Active
- 2013-08-06 WO PCT/EP2013/066443 patent/WO2014026880A1/fr not_active Ceased
- 2013-08-06 EP EP13747827.7A patent/EP2882742B1/fr active Active
- 2013-08-06 BR BR112015002921A patent/BR112015002921A2/pt not_active Application Discontinuation
- 2013-08-06 EA EA201590252A patent/EA025165B1/ru not_active IP Right Cessation
- 2013-08-06 JP JP2015526930A patent/JP5974179B2/ja active Active
- 2013-08-06 CN CN201380042690.0A patent/CN104540815B/zh active Active
- 2013-08-06 LT LTEP13747827.7T patent/LT2882742T/lt unknown
- 2013-08-06 CA CA2880257A patent/CA2880257C/fr not_active Expired - Fee Related
- 2013-08-06 MA MA37895A patent/MA37895B1/fr unknown
- 2013-08-06 DK DK13747827.7T patent/DK2882742T3/en active
- 2013-08-06 SI SI201330420A patent/SI2882742T1/sl unknown
- 2013-08-06 KR KR1020157006196A patent/KR101747005B1/ko not_active Expired - Fee Related
- 2013-08-06 AU AU2013304212A patent/AU2013304212B2/en not_active Ceased
- 2013-08-06 RS RS20161001A patent/RS55397B1/sr unknown
- 2013-08-09 TW TW102128724A patent/TWI501958B/zh not_active IP Right Cessation
- 2013-08-12 AR ARP130102851A patent/AR092097A1/es not_active Application Discontinuation
-
2015
- 2015-01-22 CR CR20150028A patent/CR20150028A/es unknown
- 2015-01-23 CO CO15013232A patent/CO7180198A2/es unknown
- 2015-01-26 ZA ZA2015/00582A patent/ZA201500582B/en unknown
- 2015-01-29 IL IL237015A patent/IL237015A/en active IP Right Grant
- 2015-02-06 CL CL2015000290A patent/CL2015000290A1/es unknown
- 2015-02-06 PH PH12015500261A patent/PH12015500261B1/en unknown
- 2015-02-13 US US14/622,232 patent/US9199971B2/en active Active
-
2016
- 2016-12-16 CY CY20161101305T patent/CY1118595T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500690A1 (en) | Positive allosteric modulators (pam) | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA33802B1 (fr) | Dérivés d'éthynyle | |
| AR093042A1 (es) | Derivados de etinilo | |
| AR106589A1 (es) | Derivados de indolin-2-ona | |
| MA37895A1 (fr) | Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité | |
| MA35196B1 (fr) | Dérivés de 2-amino-3-(inidazol-2-yl)-pyridine-4-one et utilisation de ceux-ci comme inhibiteurs de kinases associées au récepteur du vegf | |
| CO6801735A2 (es) | Derivados de pirazolidin-3-ona | |
| MA38229A1 (fr) | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| BR112014008078A2 (pt) | derivados de etinila como moduladores do receptor de glutamato metabotrópico | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| EP4271682A4 (fr) | Procédé de synthèse de composés d'indole | |
| CO2017011511A2 (es) | Derivados de indol | |
| MA37941B1 (fr) | Dérivés d'aryléthynyle | |
| TH2001006044A (th) | อนุพันธ์ของพิราโซ-เททระไฮโดรไอโซควิโนลีนในฐานะเป็นตัวควบคุมเชิงบวกของตัวรับโดพามีน d1 | |
| MA42508B1 (fr) | Dérivés d'éthynyle | |
| TH151337A (th) | มอดูเลเตอร์แบบอัลโลสเตอริกชนิดโพซิทีฟ (pam) |